NF-κB/Rel: agonist and antagonist roles in HIV-1 latency.
OBJECTIVE
To discuss recent advances in our understanding of the diverse roles of NF-κB/Rel family members in HIV-1 latency.


RESULTS
Various NF-κB/Rel family members can reinforce maintenance of HIV-1 latency. For example, p50 recruits histone deacetylase 1 to the HIV-1 long terminal repeat promoting chromatin condensation and reduced RNA Pol II recruitment. Low-level NF-κB activation during homeostatic proliferation of memory CD4 T cells induced by IL-7 and TCR signaling or OX40 action promotes expression of antiapoptotic gene targets such as BCL2 and BCLXL. Additionally, the IκB kinase phosphorylates FOXO3a transcription factor, blocking its induction of proapoptotic genes. These combined effects promote memory CD4 T-cell survival, thus maintaining the latent reservoir. Conversely, when the nontumorigenic phorbol ester prostratin is combined with histone deacetylase inhibitors, potent synergistic activation of latent HIV-1 occurs involving nuclear expression of NF-κB.


CONCLUSIONS
These recent findings highlight both the antagonistic and agonistic effects of the NF-κB signaling pathway on HIV-1 latency. Synergistic inducers might be useful for flushing of latent virus from reservoirs in infected patients. The ultimate, albeit lofty, goal is to achieve full viral eradication. However, a more reasonable goal might be a functional cure where patients experience a drug-free remission.
Gladstone Institute of Virology and Immunology, Department of Medicine, University of California, San Francisco, California, USA.
Jonathan K L
JK
Chan
Warner C
WC
Greene
D015497:HIV-1 / Q000502:physiology*; D054884:Host-Pathogen Interactions; D006801:Humans; D016328:NF-kappa B / Q000378:metabolism*; D051996:Transcription Factor RelA / Q000378:metabolism; D017735:Virus Latency
D016328:NF-kappa B; D051996:Transcription Factor RelA
J Biol Chem. 1999 Aug 13;274(33):22923-31
10438457
J Virol. 2009 Apr;83(7):3078-93
19144703
AIDS. 2009 Jul 31;23(12):1461-71
19550285
PLoS One. 2010 Feb 23;5(2):e9390
20186346
Science. 2001 Aug 31;293(5535):1653-7
11533489
Genes Dev. 2008 May 15;22(10):1356-68
18483222
J Virol. 2007 Oct;81(20):10914-23
17670825
PLoS Pathog. 2009 Aug;5(8):e1000554
19696893
J Immunol. 1996 Dec 15;157(12):5277-83
8955173
J Clin Invest. 2009 Nov;119(11):3473-86
19805909
PLoS Pathog. 2006 Jul;2(7):e68
16839202
EMBO J. 2009 Apr 22;28(8):1055-66
19262565
J Virol. 2010 Jun;84(12):5958-74
20357084
J Virol. 2010 Mar;84(6):2913-22
20032180
Mol Cell. 2001 Aug;8(2):327-37
11545735
EMBO J. 2002 Dec 2;21(23):6539-48
12456660
Genes Dev. 1990 Nov;4(11):1975-84
2125960
J Virol. 2007 Jun;81(11):6043-56
17376917
Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6321-6
19336585
J Virol. 2010 Jul;84(13):6425-37
20410271
J Immunol. 2009 Oct 15;183(8):5079-84
19786532
PLoS Pathog. 2009 Jun;5(6):e1000495
19557157
Cell Host Microbe. 2008 Aug 14;4(2):123-33
18692772
J Virol. 2004 Jun;78(12):6122-33
15163705
J Virol. 2009 Sep;83(17):8470-81
19535437
EMBO J. 2003 Apr 15;22(8):1868-77
12682019
Nat Med. 2007 Oct;13(10):1241-7
17906637
J Cell Biol. 2006 May 22;173(4):533-44
16717128
AIDS. 2002 Jul 26;16(11):1479-87
12131185
J Virol. 2000 Aug;74(15):6790-9
10888618
Nat Med. 2009 Aug;15(8):893-900
19543283
Structure. 2008 May;16(5):684-94
18462673
J Mol Biol. 2009 Oct 16;393(1):98-112
19683540
Blood. 2009 Jan 1;113(1):58-65
18849485
Mol Cell Biol. 2003 Oct;23(19):7068-81
12972622
Proc Natl Acad Sci U S A. 2009 Nov 10;106(45):18972-7
19864627
PLoS Pathog. 2009 Jan;5(1):e1000260
19132086
J Exp Med. 2007 Jan 22;204(1):79-91
17190839
PLoS One. 2009 Jun 30;4(6):e6093
19564922
EMBO J. 2006 Jan 11;25(1):139-49
16319923
J Biol Chem. 2004 Oct 1;279(40):42008-17
15284245
AIDS. 1999 Dec 3;13(17):2405-10
10597782
Mol Cell Biol. 2009 Mar;29(5):1375-87
19103749
Cell Host Microbe. 2008 Aug 14;4(2):134-46
18692773
Nat Med. 2010 Apr;16(4):446-51
20208541
J Infect Dis. 2008 Mar 1;197(5):714-20
18260759
Nat Struct Biol. 2003 Oct;10(10):800-6
12949493